WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406414
Description: SU-11752 is a potent and selective DNA-PK inhibitor. Inhibition kinetics and a direct assay for ATP binding showed that SU11752 inhibited DNA-PK by competing with ATP. SU11752 inhibited DNA double-strand break repair in cells and gave rise to a five-fold sensitization to ionizing radiation. At concentrations of SU11752 that inhibited DNA repair, cell cycle progression was still normal and ATM kinase activity was not inhibited.
MedKoo Cat#: 406414
Chemical Formula: C26H27N3O5S
Exact Mass: 493.16714
Molecular Weight: 493.57468
Elemental Analysis: C, 63.27; H, 5.51; N, 8.51; O, 16.21; S, 6.50
SU-11752 , purity > 98%, is not in stock, may be available through custom synthesis. Minimum 1 gram order is requested. Current shipping out time is about 70 days after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Shipping fee: $30.00 (USA); from $45.00 (Canada); from $70.00 (international).
Synonym: SU11752; SU11752; SU11752.
IUPAC/Chemical Name: (Z)-3-(2,4-diethyl-5-((2-oxo-5-(N-phenylsulfamoyl)indolin-3-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid
InChi Key: QUYIGDGKOSEELL-QNGOZBTKSA-N
InChi Code: InChI=1S/C26H27N3O5S/c1-3-18-19(11-13-25(30)31)22(4-2)27-24(18)15-21-20-14-17(10-12-23(20)28-26(21)32)35(33,34)29-16-8-6-5-7-9-16/h5-10,12,14-15,27,29H,3-4,11,13H2,1-2H3,(H,28,32)(H,30,31)/b21-15-
SMILES Code: O=C(O)CCC1=C(CC)NC(/C=C2C(NC3=C\2C=C(S(=O)(NC4=CC=CC=C4)=O)C=C3)=O)=C1CC
The following data is based on the product molecular weight 493.57468 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1. Finlay, M. Raymond V.; Griffin, Roger J. Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family. Bioorganic & Medicinal Chemistry Letters (2012), 22(17), 5352-5359.
2. Ljungman, Mats. Targeting the DNA Damage Response in Cancer. Chemical Reviews (Washington, DC, United States) (2009), 109(7), 2929-2950.
3. Pastwa, Elzbieta; Malinowski, Mariusz Non-homologous DNA end joining in anticancer therapy. Current Cancer Drug Targets (2007), 7(3), 243-250